Copyright
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 21, 2015; 21(43): 12403-12409
Published online Nov 21, 2015. doi: 10.3748/wjg.v21.i43.12403
Published online Nov 21, 2015. doi: 10.3748/wjg.v21.i43.12403
Surgery in (pre)malignant celiac disease
Jolanda MW van de Water, Petula Nijeboer, Laura R de Baaij, Jessy Zegers, Gerd Bouma, Chris JJ Mulder, Department of Gastroenterology and Hepatology, Coeliac Center Amsterdam, VU University Medical Center, 1007 MB Amsterdam, The Netherlands
Otto J Visser, Department of Haematology, Coeliac Center Amsterdam, VU University Medical Center, 1007 MB Amsterdam, The Netherlands
Donald L van der Peet, Wilhelmus JHJ Meijerink, Department of Surgery; Coeliac Center Amsterdam, VU University Medical Center, 1007 MB Amsterdam, The Netherlands
Author contributions: van de Water JMW and Nijeboer P contributed equally to this work; van de Water JMW, Nijeboer P, de Baaij LR, Zegers J and van der Peet DL contributed to collecting and analysing the data; van de Water JMW, Nijeboer P, Bouma G, Visser OJ, Mulder CJJ and Meijerink WJHJ contributed to writing of the manuscript; van de Water JMW and Nijeboer P contributed equally.
Institutional review board statement: According to Dutch law no ethical approval is needed for retrospective studies. Patient data in our retrospective study are anonymized.
Informed consent statement: According the Dutch law no informed consent is needed for retrospective studies. Patient data in our retrospective study are anonymized.
Conflict-of-interest statement: All authors have no conflict-of-interest.
Data sharing statement: Dataset is available from the corresponding author at cjmulder@vumc.nl. Informed consent need not be obtained as this is a retrospective study. Furthermore, data are anonymized and risk of identification is low.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Chris JJ Mulder, MD, PhD, Professor, Department of Gastroenterology and Hepatology, Coeliac Center Amsterdam, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands. cjmulder@vumc.nl
Telephone: +31-20-4440613 Fax: +31-20-4440554
Received: December 30, 2015
Peer-review started: December 30, 2015
First decision: January 22, 2015
Revised: March 29, 2015
Accepted: June 9, 2015
Article in press: June 10, 2015
Published online: November 21, 2015
Processing time: 323 Days and 6.4 Hours
Peer-review started: December 30, 2015
First decision: January 22, 2015
Revised: March 29, 2015
Accepted: June 9, 2015
Article in press: June 10, 2015
Published online: November 21, 2015
Processing time: 323 Days and 6.4 Hours
Core Tip
Core tip: A small percentage of patients with celiac disease develop (pre)malignant conditions including enteropathy associated T-cell lymphoma. No standardized treatment has been established. Surgery is indicated to relieve clinical symptoms or prevent perforation during chemotherapy. Although the frequency of early- and late post-operative complications is high, local resection is the preferred first step of treatment. Resection is preferred as early as possible after diagnosis since treatment-related mortality seems to rise in the acute setting. Early diagnosis is of utmost importance as elective surgical resection might lower the risk of post-operative mortality and improve overall survival.